A Paget disease of bone blood test usually starts with alkaline phosphatase (ALP), but diagnosis requires the ALP pattern, liver tests, bone-specific ALP when needed, and targeted imaging. Normal calcium is common in Paget disease and does not rule it out.
- Total ALP above the laboratory upper limit can signal active Paget disease, but liver and bone sources must be separated before drawing conclusions.
- Bone-specific alkaline phosphatase is useful when total ALP is normal but a scan suggests active disease, or when liver disease makes total ALP hard to interpret.
- Calcium is usually normal in uncomplicated Paget disease; a normal calcium result does not exclude the condition.
- 25-hydroxyvitamin D should generally be corrected before potent bisphosphonate treatment; many bone services aim for at least 20 ng/mL (50 nmol/L).
- GGT or 5-prime-nucleotidase helps identify a liver source of high ALP because these markers are not released substantially by bone.
- Bone scintigraphy maps the extent of metabolically active Paget disease, while targeted X-rays establish the characteristic structural changes.
- Normal ALP can occur in monostotic disease, especially when only one small bone area is involved.
- Urgent review is sensible for new weakness, hearing loss, severe night pain, a warm expanding bone, or high calcium after immobilisation.
- Monitoring commonly uses the same ALP assay before treatment and at roughly 3 to 6 months afterward, rather than comparing unmatched lab methods.
What a Paget disease blood test can and cannot show
ALP is the first-line Paget disease of bone blood test because active bone remodelling releases alkaline phosphatase into circulation, but ALP alone cannot diagnose Paget disease. As of September 23, 2026, the practical sequence is ALP plus liver-source markers, then bone-specific testing or imaging when the pattern remains uncertain.
Paget disease accelerates the normal bone renewal cycle in focal patches, producing enlarged, structurally disorganised bone. In active polyostotic disease, total ALP may be 2 to 10 times the upper reference limit; in a single affected bone, it can remain within range. That distinction prevents a surprisingly common error: treating a normal ALP as a complete exclusion test. For related metabolic causes of bone symptoms, see our osteoporosis lab guide.
In my clinical work, the patient who benefits most from this explanation is often someone with hip or skull symptoms and “normal calcium” highlighted in their portal. Calcium reflects tightly regulated extracellular physiology, not local bone turnover. Dr. Thomas Klein’s rule of thumb is simple: ALP tells us that remodelling may be active; imaging tells us where and what is happening.
Kantesti is an AI blood test analyzer that reads ALP alongside GGT, bilirubin, calcium, phosphate, kidney function and prior values rather than assigning Paget disease from one flagged result. That contextual review is especially useful when an ALP result has drifted from 94 to 168 IU/L over 18 months but still looks only mildly elevated.
Why one normal result can mislead
A normal total ALP is most likely to miss limited, inactive, or previously treated Paget disease. It also misses activity when the laboratory reference interval is broad, which is why symptoms, X-ray findings, and the number of bones involved still matter.
Reading alkaline phosphatase levels in context
Adult total ALP reference intervals commonly sit around 30 to 120 IU/L, although the exact upper limit varies by assay, age and laboratory. A result above range requires source identification before it can be attributed to bone.
ALP is produced mainly by liver and bone, with smaller intestinal and placental contributions. In an adult who is not pregnant, ALP of 145 IU/L with normal GGT and normal bilirubin makes a bone source more plausible than the same ALP with GGT 190 IU/L. Our detailed guide to high alkaline phosphatase risk explains why the absolute number is less useful than that paired pattern.
A rise of 20 IU/L may be analytically trivial in one person and clinically meaningful in another. I pay particular attention to a sustained rise exceeding the reference change value for that laboratory, new focal bone pain, or an ALP that remains elevated after a fracture should have healed. A healing fracture can raise ALP for weeks to months, so dates matter.
Children, adolescents, pregnancy, recent major fractures, hyperthyroidism, vitamin D deficiency, osteomalacia, bone metastases and hyperparathyroidism are all high ALP bone causes besides Paget disease. A single abnormal value is a prompt for clinical reasoning, not a label.
How GGT separates liver ALP from bone ALP
Normal GGT with isolated high ALP supports, but does not prove, a bone source; elevated GGT and ALP together more often point toward hepatobiliary disease or medication effects. This pairing is the quickest way to avoid confusing Paget disease with cholestasis.
GGT is present in biliary epithelium but not meaningfully released from bone, so ALP 210 IU/L plus GGT 18 IU/L is a different clinical puzzle from ALP 210 IU/L plus GGT 240 IU/L. Bilirubin, ALT, AST, albumin and medication history refine the liver side of the question. Review the common cholestatic pattern in our ALP and GGT liver guide.
ALP isoenzyme electrophoresis can separate liver and bone fractions, although it is less available than GGT or bone-specific ALP. Recent meals can transiently increase intestinal ALP in people with blood group O or B, especially secretors, which is one reason a non-fasting borderline result occasionally deserves repeating under standard conditions.
I have seen people pursue skeletal scans for an ALP rise caused by a biliary stone or an enzyme-inducing medicine. Conversely, fatty liver is common enough that a slightly raised GGT can coexist with genuine Paget disease; the answer is not always either-or.
When bone-specific alkaline phosphatase adds value
Bone-specific alkaline phosphatase measures the osteoblast-derived fraction of ALP and is most useful when total ALP is confounded by liver disease or remains normal despite suspected focal Paget disease. Laboratories report different units and methods, so each result must use its own reference interval.
Bone-specific ALP is not a universal screening test because total ALP is cheaper, widely available and usually adequate for active extensive disease. It becomes valuable in a person with primary biliary disease, MASLD, or chronic medication-related liver enzyme elevation where total ALP has lost its specificity. The same logic applies to liver panel interpretation.
Other turnover markers include serum procollagen type I N-terminal propeptide (PINP), serum C-terminal telopeptide (CTX), and urinary N-telopeptide. PINP is often more sensitive than total ALP for metabolically active Paget disease, but availability and assay consistency remain uneven across countries. Clinicians generally use one marker repeatedly rather than switching among them during follow-up.
A result may be “normal” after successful treatment while an old X-ray still looks unmistakably Pagetic. Biochemical markers track current activity; they do not reverse, erase, or fully measure the bone architecture already changed.
Why normal calcium does not rule out Paget disease
Serum calcium is normal in most people with uncomplicated Paget disease because parathyroid hormone, kidneys and gut tightly regulate calcium concentration. High calcium is unusual and should trigger a search for immobilisation, dehydration, primary hyperparathyroidism, malignancy or another cause.
Total calcium commonly measures about 8.5 to 10.5 mg/dL (2.12 to 2.62 mmol/L), but albumin affects the total value. Ionised calcium may be more informative when albumin is very low, very high, or when symptoms suggest a genuine calcium disturbance. A person can therefore have active Paget disease, ALP 330 IU/L, and calcium 9.4 mg/dL at the same appointment.
Phosphate is often normal too, although low phosphate raises the separate possibility of osteomalacia or renal phosphate wasting. PTH is not routinely required to diagnose Paget disease, but it is reasonable when calcium is high, phosphate is low, kidney function is impaired, or the clinical picture is muddled. See our guide to slightly high calcium for practical retesting issues.
The exception worth knowing is prolonged immobilisation in someone with very active, extensive disease: accelerated osteoclastic release can rarely overwhelm compensation and raise calcium. New confusion, vomiting, marked thirst or constipation with high calcium merits same-day clinical assessment.
Vitamin D testing before Paget disease treatment
A 25-hydroxyvitamin D result below 20 ng/mL (50 nmol/L) indicates deficiency in most major frameworks and should usually be corrected before intravenous zoledronic acid. Vitamin D deficiency can worsen post-infusion hypocalcaemia and can independently elevate ALP through osteomalacia.
Many bone clinics aim for 25-hydroxyvitamin D at or above 20 ng/mL before treatment, while some specialists prefer 30 ng/mL (75 nmol/L) in people with recurrent deficiency or malabsorption. The Endocrine Society’s 2024 guideline moved away from endorsing one universal higher target for healthy adults, but Paget treatment is not a routine-wellness scenario; individual risk still matters (Demay et al., 2024).
Vitamin D deficiency commonly causes secondary hyperparathyroidism, low-normal calcium, low phosphate and increased ALP. That overlap means a deficient person should not be diagnosed with Paget disease from ALP alone. Our vitamin D retest schedule explains why rechecking is usually delayed by weeks rather than days.
In my experience, correcting a 25-hydroxyvitamin D level of 11 ng/mL before therapy avoids a preventable rough few days of tingling, cramps or fatigue after an infusion. The exact replacement regimen depends on kidney function, calcium, malabsorption and clinician preference.
Which scans confirm Paget disease diagnosis
Targeted plain X-rays establish Paget disease diagnosis by showing characteristic bone enlargement, cortical thickening, mixed lytic-sclerotic change and altered trabecular pattern. A radionuclide bone scan then identifies how many bones are metabolically active.
An X-ray is not replaced by a blood test. The skull, pelvis, femur, tibia and lumbar spine are frequent sites, and one carefully selected radiograph can be diagnostic when interpreted in the right clinical setting. CT or MRI is generally reserved for complications such as nerve compression, fracture assessment, spinal stenosis or concern about an unusual transformation.
Bone scintigraphy uses a bone-seeking tracer to show active remodelling throughout the skeleton; it may find asymptomatic sites that change treatment discussions. An inactive sclerotic Pagetic bone can show little tracer uptake, so scan activity and X-ray structure are complementary rather than competing findings.
If pain is not at a known Paget site, clinicians should resist assuming it is caused by Paget disease. Osteoarthritis, spinal stenosis, insufficiency fracture and nerve-root pain are common alternatives. A focused unexplained pain blood-test review can help frame the broader differential.
Putting ALP, symptoms and scans into one diagnosis
Paget disease diagnosis is strongest when characteristic imaging is paired with elevated bone turnover markers or compatible symptoms; no single blood marker confirms it. A normal ALP does not overrule an unmistakable X-ray, and a high ALP does not overrule a liver-pattern panel.
A practical pattern is: ALP 286 IU/L, GGT 22 IU/L, calcium 9.2 mg/dL, vitamin D 31 ng/mL, focal pelvic pain, and X-ray changes in the hemipelvis. That combination makes active Paget disease plausible enough for specialist confirmation. The same ALP with GGT 180 IU/L, jaundice and normal skeletal imaging calls for a different route entirely.
Kantesti is an AI blood test interpretation platform that groups these data by physiological source and makes trend comparisons visible across separate reports. Our system cannot diagnose from an uploaded PDF, but it can flag the “isolated ALP plus normal GGT” pattern for clinician follow-up and preserve the exact assay history.
One nuance rarely discussed: pain severity and ALP height correlate imperfectly. A small active lesion near a weight-bearing joint can hurt substantially with ALP 135 IU/L, whereas extensive but biomechanically quiet disease may produce a much higher ALP with few symptoms. Read how to preserve comparable results in our longitudinal lab guide.
High ALP bone causes that can resemble Paget disease
Vitamin D deficiency, healing fractures, hyperparathyroidism, hyperthyroidism, osteomalacia, bone metastases and high-turnover renal bone disease can all raise ALP without Paget disease. The right next test depends on age, symptoms, medication use, calcium-phosphate pattern and imaging.
Recent fracture healing can increase total ALP, often beginning after the first week and peaking during active callus formation, though the magnitude varies widely. This is why a history of surgery, trauma, dental bone grafting or stress fracture belongs on the lab request. Our guide to ALP after a fracture covers the timing in more detail.
Primary hyperparathyroidism more often produces high calcium with low-normal phosphate, while vitamin D deficiency often produces low-normal calcium with elevated PTH. Chronic kidney disease can add high phosphate and secondary hyperparathyroidism, making interpretation more complex; estimated GFR changes the safety plan for several treatments.
Cancer is a possibility when ALP is persistently high and symptoms or imaging are concerning, but ALP is not a cancer test. Unexplained weight loss, night pain that is progressive, a new hard swelling, or anaemia should accelerate clinical review rather than lead to self-diagnosis.
When active Paget disease needs treatment
Bisphosphonate treatment is usually considered for symptomatic active Paget disease and for selected high-risk sites, rather than solely because ALP is above range. A single 5 mg intravenous zoledronic acid infusion often produces prolonged biochemical remission when it is safe to use.
The 2019 international clinical guideline recommends bisphosphonates for Paget-related bone pain, with zoledronic acid favoured for pain response when no contraindication exists (Ralston et al., 2019). Treat-to-target ALP suppression is biologically satisfying, but evidence that treating every asymptomatic biochemical elevation prevents future complications remains uncertain.
Before intravenous therapy, clinicians commonly check creatinine or eGFR, calcium, phosphate and 25-hydroxyvitamin D. Zoledronic acid is generally avoided or used only with specialist judgement in significant renal impairment; the product-specific renal threshold and local protocol matter. Kidney context is covered in our eGFR and CKD guide.
Dental assessment is individualised rather than automatic. Medication-related jaw osteonecrosis is very rare at osteoporosis- or Paget-level bisphosphonate exposure, but a planned major dental extraction, poor oral health, cancer-dose antiresorptives or steroid use may change the timing conversation.
How to monitor ALP after treatment
Total ALP or bone-specific ALP is commonly rechecked about 3 to 6 months after treatment, using the same laboratory method whenever possible. A large fall toward the reference interval supports biochemical response but does not guarantee that every pain symptom will resolve.
A baseline ALP of 420 IU/L falling to 110 IU/L after zoledronic acid is a clear biochemical response if the laboratory upper limit is 120 IU/L. If it falls only from 420 to 320 IU/L, clinicians reassess adherence to calcium and vitamin D advice, the original diagnosis, ongoing disease activity, assay consistency and whether another ALP source is contributing.
Repeat imaging is not automatically needed for every improving marker. It is more useful for a changing focal symptom, suspected fracture, neurological complaint, deformity, or a lesion at risk of structural complication. Some patients need only occasional clinical and biochemical surveillance after successful treatment.
Kantesti AI can compare dated ALP, GGT, calcium, vitamin D and kidney results across reports, but trend interpretation still needs clinical ownership. Small variations of 5 to 10 IU/L can reflect normal biological and analytical variation rather than relapse. See our meaningful lab change guide before reacting to a minor shift.
Symptoms and red flags that should not wait
New neurological symptoms, sudden inability to bear weight, rapidly escalating bone pain, new hearing loss or symptoms of high calcium warrant prompt medical assessment in a person with suspected or known Paget disease. These features can signal complications rather than routine biochemical activity.
Paget disease can cause deep aching bone pain, warmth over an active site, altered bone shape, secondary osteoarthritis, headache, hearing change or nerve compression. Hearing loss is often multifactorial in older adults, so it deserves formal assessment rather than an assumption that Paget disease is the sole explanation.
A sudden severe pain in the femur or tibia after little trauma may represent an incomplete fracture through structurally altered bone. New leg weakness, numbness around the groin, bladder changes or bowel changes are emergency symptoms because spinal compression needs rapid assessment.
Dr. Thomas Klein advises patients to bring the actual laboratory report, medication list, and prior imaging dates to an urgent appointment. A concise blood-test visit summary is often more useful than trying to recall ALP values from memory.
Questions to ask after an abnormal ALP result
The first question after high ALP is “is this coming from bone, liver, or both?” The next is whether symptoms, prior results and targeted imaging support active Paget disease. Asking these questions keeps the assessment focused without prematurely naming a diagnosis.
Ask whether GGT, bilirubin and ALT were checked; whether bone-specific ALP or PINP would add information; and whether vitamin D, calcium, phosphate, PTH and kidney function alter the differential. Also ask whether a recent fracture, thyroid disease, supplement, anticonvulsant, pregnancy or liver condition could explain the result.
If imaging is planned, ask which symptomatic or high-yield bone will be X-rayed first and whether a bone scan is needed after that. A scan maps distribution; it does not replace a diagnostic radiograph. This distinction saves people from falsely reassured or unnecessarily alarmed interpretations.
Kantesti is an AI-powered blood test analysis tool used across 127 countries to organise laboratory trends and plain-language questions for follow-up. Our clinical methodology and escalation boundaries are described in our medical validation framework, and our advice never replaces the clinician who can examine you and review imaging.
A practical next-step plan for Paget testing
For isolated elevated ALP, arrange a non-urgent clinician review within weeks unless red-flag symptoms are present; repeat or extend testing with GGT, liver panel, calcium, phosphate, 25-hydroxyvitamin D and kidney function as indicated. Imaging follows when a bone source or symptoms make Paget disease plausible.
Keep the original report and note whether you were fasting, recently ill, immobilised, recovering from a fracture, or starting a new medicine. Repeat testing is often most useful after 4 to 12 weeks when a mild unexplained ALP elevation has no urgent features, but a clinician may move faster if ALP is several-fold elevated or symptoms are focal.
Do not start high-dose vitamin D, calcium or bone-active supplements simply to “fix” a result before the work-up. Vitamin D replacement is frequently appropriate, but large unsupervised calcium doses can complicate assessment in people with hypercalcaemia, kidney disease or primary hyperparathyroidism. For a safer preparation checklist, read baseline blood-test planning.
Our physician reviewers and Medical Advisory Board support a cautious approach: use the result to start a conversation, not to self-treat. Most patients find that once ALP is sourced correctly and imaging is chosen deliberately, the uncertainty becomes far more manageable.
Frequently Asked Questions
Can you diagnose Paget disease of bone with a blood test?
No, a blood test cannot diagnose Paget disease of bone by itself. Total alkaline phosphatase is often elevated in active disease, but liver disorders, vitamin D deficiency, fracture healing and other bone conditions can produce the same finding. Characteristic X-ray changes establish the diagnosis, while a bone scan commonly maps the extent of active disease. Normal ALP can occur when Paget disease affects only one small bone area or is inactive.
What ALP level suggests Paget disease?
There is no single ALP cutoff that proves Paget disease. Adult laboratories commonly use an upper limit near 120 IU/L, and active extensive Paget disease may raise ALP to 2 to 10 times that limit, but a result of 150 IU/L can still be meaningful if GGT is normal and imaging is compatible. Conversely, ALP above 300 IU/L may come from liver or bile duct disease. The source pattern and imaging matter more than any isolated threshold.
Can Paget disease cause high calcium?
Uncomplicated Paget disease usually causes normal serum calcium, typically about 8.5 to 10.5 mg/dL or 2.12 to 2.62 mmol/L. High calcium is unusual and should prompt evaluation for primary hyperparathyroidism, malignancy, dehydration, supplements, kidney problems or prolonged immobilisation with extensive active disease. Normal calcium therefore does not rule out Paget disease. Calcium should be interpreted with albumin or, in selected cases, ionised calcium.
Why is bone-specific alkaline phosphatase tested?
Bone-specific alkaline phosphatase estimates the portion of ALP released by osteoblast activity rather than liver tissue. It is especially useful when total ALP is elevated but GGT or other liver tests are also abnormal, or when total ALP is normal despite a suspicious bone scan. Laboratories use different assays and units, so a bone-specific ALP result must be compared with that laboratory’s own reference interval. It supports assessment of active bone turnover but still does not replace diagnostic imaging.
Should vitamin D be checked before Paget disease treatment?
Yes, 25-hydroxyvitamin D is commonly checked before potent bisphosphonate treatment for Paget disease. A level below 20 ng/mL or 50 nmol/L is generally considered deficient and can increase the chance of low calcium symptoms after intravenous zoledronic acid. Vitamin D deficiency can also elevate ALP through osteomalacia, making the diagnosis less clear. The replacement dose and timing should account for calcium, kidney function, malabsorption and clinician guidance.
How often should ALP be checked after Paget treatment?
ALP or another chosen bone-turnover marker is often rechecked about 3 to 6 months after treatment, preferably using the same assay and laboratory. A substantial decline toward the laboratory reference interval supports a biochemical response, while a small change of 5 to 10 IU/L may merely reflect ordinary variation. Further testing intervals depend on symptoms, initial disease extent, treatment response and whether ALP was a reliable marker at baseline. New focal pain or neurological symptoms should prompt review regardless of the next scheduled test.
Get AI-Powered Blood Test Analysis Today
Join over 2 million users worldwide who trust Kantesti for instant, accurate lab test analysis. Upload your blood test results and receive comprehensive interpretation of 15,000+ biomarkers in seconds.
📚 Referenced Research Publications
Klein, T., Mitchell, S., & Weber, H. (2026). aPTT Normal Range: D-Dimer, Protein C Blood Clotting Guide. Kantesti AI Medical Research.
Klein, T., Mitchell, S., & Weber, H. (2026). Serum Proteins Guide: Globulins, Albumin & A/G Ratio Blood Test. Kantesti AI Medical Research.
📖 External Medical References
Demay MB et al. (2024). Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism.
⚕️ Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.
E-E-A-T Trust Signals
Experience
Physician-led clinical review of lab interpretation workflows.
Expertise
Laboratory medicine focus on how biomarkers behave in clinical context.
Authoritativeness
Written by Dr. Thomas Klein with review by Dr. Sarah Mitchell and Prof. Dr. Hans Weber.
Trustworthiness
Evidence-based interpretation with clear follow-up pathways to reduce alarm.